BETALIFE PTE. LTD.

BetaLife is focused on developing cell therapy for diabetes patients, to meet the need for a next generation curative treatment for diabetes. We will do this by generating high quality clinical-grade human induced pluripotent stem cells (hiPSCs) that are developed into pancreatic beta cells for cell replacement therapy. We are also focused on developing products and services that benefit the rising demand for hiPSC-based research and clinical applications worldwide. For more information please refer to https://betalife.sg/.

BetaLife 专注于为糖尿病患者开发细胞疗法，以满足对下一代治愈性治疗的需求。我们通过生成高质量临床级人类诱导多能干细胞（hiPSCs），并将其开发为胰腺 β 细胞用于细胞替代疗法。我们还专注于开发产品和服务，以满足全球对基于 hiPSC 的研究和临床应用日益增长的需求。更多信息请访问 https://betalife.sg/。